IL6 and rheumatoid arthritis: The main strength of our study is that it includes systematic clinical and biochemical evaluations of 27 RA patients undergoing systemic IL-6 inhibition during 1-year of follow-up using multivariable linear mixed models for the analysis, allowing us to examine the long-term effects of TCZ on complement pathways.